Neoadjuvant concurrent chemotherapy and radiotherapy in non-small cell lung cancer.
Abstract. Radiotherapy was the standard treatment for patients with locally advanced non-small cell lung cancer until the mid 1990s. Chemotherapy was added in order to improve outcome, and during the last decade sequential, concurrent or mixed modalities have been extensively explored and discussed. Goals of neoadjuvant chemoradiation are resecability and downstaging. Recent published experiences evidenced that neoadjuvant chemoradiotherapy is feasible if delivered with low total dose and limited volume; pathological downstaging to stage 0-I could be a reasonable surrogate end-point for overall and disease free survival and for distant metastasis.
Ramella
Sara
S
Istituto di Radiologia, Cattedra Radioterapia, Università Cattolica del S.Cuore, Policlinico "A. Gemelli", Roma, Italy. sara_ramella@virgilio.it
Ciresa
Marzia
M
Massaccesi
Mariangela
M
Franceschini
Gianluca
G
D'Angelillo
Rolando M
RM
Trodella
Lucio
L
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D020360:Neoadjuvant Therapy; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D016896:Treatment Outcome